Company Overview - Dize Pharmaceutical has submitted its listing application to the Hong Kong Stock Exchange, with Goldman Sachs and Huatai International as joint sponsors [1] - The company is a commercial-stage biopharmaceutical firm focusing on oncology and hematological diseases [1] Core Products - The core drug, Shuwozhe, is the only approved small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for treating EGFR 20 insertion mutation lung cancer globally [1] - Shuwozhe is the first lung cancer drug developed in China to receive breakthrough therapy designation from both the FDA and the National Medical Products Administration of China [1] - It is the only targeted drug recommended by the NCCN guidelines for non-small cell lung cancer (NSCLC) and included in China's national medical insurance catalog for this indication as of January 18, 2026 [1] - The second core drug, Gaoruizhe, is the first and only approved JAK1 inhibitor for treating relapsed or refractory peripheral T-cell lymphoma [1] - Gaoruizhe has received fast track and orphan drug designations from the FDA and is also included in China's national medical insurance catalog [1] Pipeline and Market Potential - In addition to the two approved drugs, the pipeline includes one asset in the registration clinical stage, three in the post-concept validation stage, and one in the early clinical stage [1] - The global and Chinese oncology drug markets are experiencing significant growth, particularly in the treatment of lung cancer and NSCLC, which have substantial unmet medical needs [1] - The global market for EGFR 20 insertion mutation NSCLC is projected to grow from $1 billion in 2024 to $8 billion by 2035 [1]

Company Overview - Dize Pharmaceutical Co., Ltd. is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases, with its core product, Shuwozhe®, being the only approved small molecule EGFR tyrosine kinase inhibitor for treating EGFR 20 insertion mutation lung cancer globally [3][4] - Founded in 2017, Dize originated from AstraZeneca's global oncology translational science center, possessing significant competitive advantages in drug discovery and development [3] - The company has a robust product pipeline, including two approved drugs (Shuwozhe® and Gaoruozhe®), one candidate in the registration clinical stage, three assets in the concept validation stage, and one in early clinical stage [3] Financial Performance - Revenue for the fiscal years 2023, 2024, and the nine months ending September 30, 2025, were approximately RMB 91.29 million, RMB 360 million, and RMB 586 million respectively [5][7] - Research and development expenses for the same periods were approximately RMB 806 million, RMB 724 million, and RMB 644 million respectively [6][8] - Gross profit margins for 2023, 2024, and the nine months ending September 30, 2025, were approximately 96.5%, 97.4%, and 95.7% respectively [9][10] Industry Overview - The global oncology drug market is projected to grow from USD 167 billion in 2020 to USD 262 billion by 2024, with a compound annual growth rate (CAGR) of 11.9%, and expected to reach USD 724.9 billion by 2035 [11] - In China, the oncology drug market is expected to grow from USD 25.8 billion in 2020 to USD 37.2 billion by 2024, with a CAGR of 13.1%, reaching USD 143.7 billion by 2035 [11] - Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, with the global incidence expected to rise from about 1.9 million cases in 2020 to 2.9 million by 2035 [14] - The global NSCLC drug market is projected to grow from USD 22.5 billion in 2020 to USD 49.2 billion by 2024, with a CAGR of 21.6%, and expected to reach USD 97.5 billion by 2035 [14]

Company Overview - Zeling Bio has submitted a listing application to the Hong Kong Stock Exchange, with joint sponsors Jefferies and CICC [1] - The company is a late-stage clinical biotechnology firm focused on integrating structural biology, artificial intelligence, and clinically relevant disease models to develop highly differentiated small molecule therapies [1] - Zeling Bio targets significant unmet medical needs in hematologic diseases, oncology, central nervous system disorders, and immune/inflammatory diseases, possessing eight proprietary assets in clinical and preclinical stages [1] Product Pipeline - The core product, Fluorotinib (FM), is in Phase 3 registration clinical trials for the treatment of myelofibrosis, a type of myeloproliferative neoplasm [1] - FM is a novel triple-target inhibitor of Janus kinase 2, FMS-like tyrosine kinase 3, and cyclin-dependent kinase 6 [1] - Another product, Pidilizumab (PM), is also in Phase 3 registration clinical trials for the treatment of relapsed/refractory diffuse large B-cell lymphoma, designed as a next-generation selective HDAC I/IIb inhibitor emphasizing selectivity and safety [1] Industry Insights - The global oncology therapeutics market is projected to grow from $262.1 billion in 2024 to $724.9 billion by 2035 [2] - The Chinese oncology therapeutics market is expected to expand from $37.2 billion in 2024 to $143.7 billion by 2035 [2] - The global myelofibrosis therapeutics market is anticipated to increase from $3 billion in 2024 to $11.1 billion by 2035, with a compound annual growth rate of 14.6% expected in the Chinese market during the same period [2]

Core Viewpoint - Sangfor Pharmaceuticals (01530) has seen a significant stock increase of over 160% in the past two months, with a current price of 32.8 HKD and a trading volume of 404 million HKD [1] Group 1: Market Potential - The global licensing agreement between Sangfor Pharmaceuticals and Pfizer for the PD-1*VEGF dual antibody SSGJ-707 is set to take effect in July 2025, with a potential market size of 200 billion USD [1] - The PD(L)1 monoclonal antibody market is expected to reach 100 billion USD by 2029, indicating substantial growth in cancer treatment standards [1] Group 2: Sales Forecast - The peak sales potential for SSGJ-707 in China is estimated to reach between 6.3 billion to 8.4 billion CNY, while the global peak sales potential is projected to be between 11.3 billion to 13.4 billion USD [2] - Pfizer's oncology business focuses on breast cancer, hematological malignancies, thymic tumors, and bladder cancer, with plans to combine SSGJ-707 with existing drugs to cover over 500,000 frontline patients in Europe and the US [2]